A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 79
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : ORRs
Long Form : objective response rates
No. Year Title Co-occurring Abbreviation
2020 A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. AE's, CI, DDLS, DSRCT, LMS, MLS, PFS, PR, SD, SD, SS, STS
2020 A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies. DLT
2020 Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials. PD-1
2020 Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. OS, PD-L1, PFS
2020 Benchmarking single-arm studies against historical controls from non-small cell lung cancer trials - an empirical analysis of bias. NSCLC, OS, PFS, RCTs
2020 Clinical activity of programmed cell death 1 (PD-1) blockade in never, light,and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50. DOR, HR, ICIs, NSCLC, PD-1, PD-L1, PFS, TMB, TPS
2020 Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75years old from multiple Japanese institutes. AEs, mRCC, OS, PFS
2020 Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer. CI, DCRs, OS, PFS
2020 Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. CI, HR, OS, PD-1, PD-L1, PFS
10  2020 Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma). BTC, ICI, TME
11  2020 Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array. HCC, LEN, MTA, OS, SOR
12  2020 Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801. AUC, GEM, NSCLC, OSs, PFS
13  2020 Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma. AEs, DCRs, mPFS
14  2020 Selective Vascular Endothelial Growth Factor Receptor Inhibitors Provide Limited Benefits for Metastatic Colorectal Cancer: A Meta-Analysis. 5-FU, AE, ALP, AST, CR, DCRs, mCRC, OS, PD, PFS, PR, RCTs, SD, TEAEs, VEGFR
15  2020 Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India. ADCAs, EGFR, Exon 19 Del, NSCLC, TKIs
16  2020 Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors? ADCs, AEs, EV, ICI, SG
17  2020 The impact of molecular subtype on efficacy of chemotherapy and checkpoint inhibition in advanced gastric cancer. AGC, PFS
18  2020 The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. anti-PD-1, COX, NSAIDs, OS, PFS
19  2020 Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. AEs, CI, HR, NS-NSCLC, PFS
20  2019 Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy. CRC, PFS and OS
21  2019 Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors. NSCLC, PD-1, PD-L1, TMB
22  2019 DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade. AUC, ICI, KEGG, TMB
23  2019 Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma. ICERs, ICURs, PFS
24  2019 Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. AE, CI, PLGG
25  2019 Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy. HRR, TNBC
26  2019 Immunosuppressive therapy with rabbit antithymocyte globulin therapy for acquired aplastic anemia: a multi-institutional retrospective study in Japanese adult patients. AA, CsA, OS, rATG
27  2019 Management of CNS metastases in patients with EGFR mutation-positive NSCLC. BBB, CNS, EGFR, NCCN, NSCLC, PFS, TKIs
28  2019 Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients. IT, PFS, PMME
29  2019 Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer. AUC, NSCLC, PFSs
30  2019 Real world experience on treatment, outcome and toxicity of crizotinib in patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer. ALK, BM, FISH, IHC, JHSIMC, NSCLC, OS, PFS, TTSH
31  2019 Robust immunoscore model to predict the response to anti-PD1 therapy in melanoma. LASSO
32  2019 The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. anti-PD-1, COX, NSAIDs, OS, PFS
33  2019 The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism? AEs, ICIs
34  2019 [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma]. ADx-ARMS, ADx-SuperARMS, EGFR, EGFR-TKIs, PFS
35  2018 Alectinib: A Review in Advanced, ALK-Positive NSCLC. AEs, ALK, CNS, NSCLC, PFS
36  2018 Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer. NSCLC, OS, PD-L1
37  2018 Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation. AEs, amRCC, BSC, CrIs, HRQoL, HRs, ICER, MTC, OS, PFS, QALY, RCTs, SAs, VEGF
38  2018 Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer. ALK, NSCLC, PFS
39  2018 Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis. DCRs, GC, HCC, NSCLC
40  2018 Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study. AE, CR, HCC, HFS, OS, PFS, PR, SD
41  2018 Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. ALK, iPFS
42  2018 Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer. LCBI, PD-1, PD-L1, SCAI
43  2018 PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. CLL, PD-L1
44  2018 Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis. ABC, CI, ctDNA, DCRs, HRs, PFS, PI3K, RRs, SOC
45  2018 Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. CI, IMDC, mRCC, OS, PFS
46  2017 A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials. SDR
47  2017 Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1). ADCs, PFS, PK-PD
48  2017 Droplet digital PCR improved the EGFR mutation diagnosis with pleural fluid samples in non-small-cell lung cancer patients. ARMS, ddPCR, EGFR, NSCLC, PFS
49  2017 Immunotherapy in the Elderly. ---
50  2017 Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. DOR, IRF, laBCC, mBCC, OS
51  2017 Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer. AEs, EGFR, PFS, TKI
52  2017 The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series. ---
53  2016 Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. CI, HR, MTC, PFS, RET
54  2016 Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation. AEs, HRQoL, OS, PFS
55  2016 EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. NSCLC, OS, PFS, TKI
56  2016 Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. IO, NSCLC, RCC
57  2016 SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. PFS, SIRT
58  2016 The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. CI, OS, PFS
59  2015 BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis. DCRs, EGFR, NSCLC, OR, PFS, TKI's
60  2015 Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. AEs, DCRs, NSCLC, OS, PFS, RCTs
61  2015 No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma. mRCC, PFS, TKIs
62  2015 RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. FFS, mRCC, TTP
63  2015 Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. HRs, OS, PFS, ULMS
64  2015 Shedding light on the molecular determinants of response to anti-PD-1 therapy. NSCLC, PD-1, PD-L1
65  2014 FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. FDA, NSCLC, OS, PFS
66  2014 Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. NSCLC, PFS
67  2014 Temporal changes in the efficacy of chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysis. PF
68  2013 A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). AEs, EGFR, NSCLC, OS, PFS
69  2013 In vitro chemosensitivity assay of ascites in epithelial ovarian cancer. EOC, PTX, RECIST, TTP
70  2013 Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. CI, OS, PCb, RT
71  2012 Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. CI, MBC, PFS
72  2011 Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer. ACRC, DCRs, PFS
73  2011 Novel immunotherapeutic strategies of gastric cancer treatment. GC, OS
74  2011 Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. ARMS, EGFR, NSCLC, OS, PFS, TKIs
75  2009 Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study. MST, nonsquamous histology, NSCLC, PFS, squamous histology
76  2008 Review article: panitumumab--a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. EGFR, mCRC
77  2004 Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. MBC, QOL
78  2003 A review of phase II studies of ZD9331 treatment for relapsed or refractory solid tumours. NSCLC
79  1999 Expanding options in breast cancer. ---